

RESEARCH OPPORTUNITY

NAMI is committed to ensuring that the most effective treatments for mental illness are available to those who need them. Determining which treatments are most effective requires research. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and Chief Program Officer Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved by an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting clinical trial participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these trials.

If you have questions about research at NAMI, please visit [NAMI.org/research](https://www.nami.org/research) or email us at research@nami.org.

WHAT IS THE STUDY?

This study is a clinical research trial of an investigational medication for people with depression whose current antidepressant is not fully managing their symptoms. The trial will determine if the investigational medication is safe and effective for reducing depression symptoms. Participants will be randomly assigned to receive the investigational medication or placebo, once a day, by mouth, for 28 days. All participants will continue taking their current antidepressant throughout the study. Total participation time, including screening, treatment, and follow up, is up to 10 weeks. Participants may be reimbursed for time and travel. The goal of this study is to increase treatment options available for people who are not experiencing adequate symptom relief from their current antidepressant medication.

WHO CAN PARTICIPATE?

Participants may be eligible for this study if they are:

- Aged 18-65
- Diagnosed with major depressive disorder (MDD)
- Currently experiencing depression/a depressive episode

There will be 300 people participating in this study.

WHERE IS THE STUDY TAKING PLACE?

There are multiple study sites located across the U.S.

HOW DO I LEARN MORE?

Additional information is included in the study brochure and study flyer. If you have questions or would like more information, please visit <https://www.relmadastudies.com/> or contact the research team at clinicaltrials@relmada.com or (786) 638-7384.